Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity

Anthony A. Horner, Kenji Takabayashi, Lucinda Beck, Bhavya Sharma, Jose Zubeldia, Stephen Baird, Stephan Tuck, Lev Libet, Hans L. Spiegelberg, Fu-Tong Liu, Eyal Raz

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Immunotherapy has gradually fallen out of favor for the treatment of many allergic diseases because of the overall convenience, safety, and efficacy of medications. However, investigations suggest that allergen/immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) conjugates (AICs) might have improved safety and efficacy compared with allergen extracts. Objective: We determined whether changes in the ISS-ODN conjugation ratio would effect the immunogenicity and allergenicity of AIC. Methods: Immunogenicity was determined by means of AIC vaccination of mice, followed by analysis of antigen-specific antibody and cytokine responses. The allergenicity of AIC was determined in mast cell release studies and in murine models of anaphylaxis and the Arthus reaction. Results: AIC induced a stronger immune response than allergen alone or allergen mixed with ISS-ODN, but higher-level ISS-ODN conjugation reduced its immunogenicity modestly. In mast cell degranulation studies AIC was approximately 100-fold less allergenic than native allergen, with stepwise increases in the ODN conjugation ratio leading to stepwise decreases in allergenicity. In anaphylaxis studies death rates were reduced from 100% with native allergen challenge to as low as 0% with high-ratio ISS-ODN AIC challenge. Similar results were obtained in an Arthus reaction model. Conclusion: These investigations establish that AIC is both significantly more immunogenic and less allergenic than native allergens and the techniques used might have further utility for the standardization and optimization of AIC formulations for use in allergic patients.

Original languageEnglish (US)
Pages (from-to)413-420
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume110
Issue number3
DOIs
StatePublished - Sep 2002

Fingerprint

Oligodeoxyribonucleotides
Allergens
Arthus Reaction
Anaphylaxis
Mast Cells
Safety
Cell Degranulation
Immunotherapy
Antibody Formation
Vaccination
Cytokines
Antigens
Mortality

Keywords

  • Anaphylaxis
  • CpG motif immunotherapy
  • Immunostimulatory DNA

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. / Horner, Anthony A.; Takabayashi, Kenji; Beck, Lucinda; Sharma, Bhavya; Zubeldia, Jose; Baird, Stephen; Tuck, Stephan; Libet, Lev; Spiegelberg, Hans L.; Liu, Fu-Tong; Raz, Eyal.

In: Journal of Allergy and Clinical Immunology, Vol. 110, No. 3, 09.2002, p. 413-420.

Research output: Contribution to journalArticle

Horner, AA, Takabayashi, K, Beck, L, Sharma, B, Zubeldia, J, Baird, S, Tuck, S, Libet, L, Spiegelberg, HL, Liu, F-T & Raz, E 2002, 'Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity', Journal of Allergy and Clinical Immunology, vol. 110, no. 3, pp. 413-420. https://doi.org/10.1067/mai.2002.126660
Horner, Anthony A. ; Takabayashi, Kenji ; Beck, Lucinda ; Sharma, Bhavya ; Zubeldia, Jose ; Baird, Stephen ; Tuck, Stephan ; Libet, Lev ; Spiegelberg, Hans L. ; Liu, Fu-Tong ; Raz, Eyal. / Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. In: Journal of Allergy and Clinical Immunology. 2002 ; Vol. 110, No. 3. pp. 413-420.
@article{c4f8c9cdc80048ff915ecfcfbe90a3b8,
title = "Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity",
abstract = "Background: Immunotherapy has gradually fallen out of favor for the treatment of many allergic diseases because of the overall convenience, safety, and efficacy of medications. However, investigations suggest that allergen/immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) conjugates (AICs) might have improved safety and efficacy compared with allergen extracts. Objective: We determined whether changes in the ISS-ODN conjugation ratio would effect the immunogenicity and allergenicity of AIC. Methods: Immunogenicity was determined by means of AIC vaccination of mice, followed by analysis of antigen-specific antibody and cytokine responses. The allergenicity of AIC was determined in mast cell release studies and in murine models of anaphylaxis and the Arthus reaction. Results: AIC induced a stronger immune response than allergen alone or allergen mixed with ISS-ODN, but higher-level ISS-ODN conjugation reduced its immunogenicity modestly. In mast cell degranulation studies AIC was approximately 100-fold less allergenic than native allergen, with stepwise increases in the ODN conjugation ratio leading to stepwise decreases in allergenicity. In anaphylaxis studies death rates were reduced from 100{\%} with native allergen challenge to as low as 0{\%} with high-ratio ISS-ODN AIC challenge. Similar results were obtained in an Arthus reaction model. Conclusion: These investigations establish that AIC is both significantly more immunogenic and less allergenic than native allergens and the techniques used might have further utility for the standardization and optimization of AIC formulations for use in allergic patients.",
keywords = "Anaphylaxis, CpG motif immunotherapy, Immunostimulatory DNA",
author = "Horner, {Anthony A.} and Kenji Takabayashi and Lucinda Beck and Bhavya Sharma and Jose Zubeldia and Stephen Baird and Stephan Tuck and Lev Libet and Spiegelberg, {Hans L.} and Fu-Tong Liu and Eyal Raz",
year = "2002",
month = "9",
doi = "10.1067/mai.2002.126660",
language = "English (US)",
volume = "110",
pages = "413--420",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity

AU - Horner, Anthony A.

AU - Takabayashi, Kenji

AU - Beck, Lucinda

AU - Sharma, Bhavya

AU - Zubeldia, Jose

AU - Baird, Stephen

AU - Tuck, Stephan

AU - Libet, Lev

AU - Spiegelberg, Hans L.

AU - Liu, Fu-Tong

AU - Raz, Eyal

PY - 2002/9

Y1 - 2002/9

N2 - Background: Immunotherapy has gradually fallen out of favor for the treatment of many allergic diseases because of the overall convenience, safety, and efficacy of medications. However, investigations suggest that allergen/immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) conjugates (AICs) might have improved safety and efficacy compared with allergen extracts. Objective: We determined whether changes in the ISS-ODN conjugation ratio would effect the immunogenicity and allergenicity of AIC. Methods: Immunogenicity was determined by means of AIC vaccination of mice, followed by analysis of antigen-specific antibody and cytokine responses. The allergenicity of AIC was determined in mast cell release studies and in murine models of anaphylaxis and the Arthus reaction. Results: AIC induced a stronger immune response than allergen alone or allergen mixed with ISS-ODN, but higher-level ISS-ODN conjugation reduced its immunogenicity modestly. In mast cell degranulation studies AIC was approximately 100-fold less allergenic than native allergen, with stepwise increases in the ODN conjugation ratio leading to stepwise decreases in allergenicity. In anaphylaxis studies death rates were reduced from 100% with native allergen challenge to as low as 0% with high-ratio ISS-ODN AIC challenge. Similar results were obtained in an Arthus reaction model. Conclusion: These investigations establish that AIC is both significantly more immunogenic and less allergenic than native allergens and the techniques used might have further utility for the standardization and optimization of AIC formulations for use in allergic patients.

AB - Background: Immunotherapy has gradually fallen out of favor for the treatment of many allergic diseases because of the overall convenience, safety, and efficacy of medications. However, investigations suggest that allergen/immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) conjugates (AICs) might have improved safety and efficacy compared with allergen extracts. Objective: We determined whether changes in the ISS-ODN conjugation ratio would effect the immunogenicity and allergenicity of AIC. Methods: Immunogenicity was determined by means of AIC vaccination of mice, followed by analysis of antigen-specific antibody and cytokine responses. The allergenicity of AIC was determined in mast cell release studies and in murine models of anaphylaxis and the Arthus reaction. Results: AIC induced a stronger immune response than allergen alone or allergen mixed with ISS-ODN, but higher-level ISS-ODN conjugation reduced its immunogenicity modestly. In mast cell degranulation studies AIC was approximately 100-fold less allergenic than native allergen, with stepwise increases in the ODN conjugation ratio leading to stepwise decreases in allergenicity. In anaphylaxis studies death rates were reduced from 100% with native allergen challenge to as low as 0% with high-ratio ISS-ODN AIC challenge. Similar results were obtained in an Arthus reaction model. Conclusion: These investigations establish that AIC is both significantly more immunogenic and less allergenic than native allergens and the techniques used might have further utility for the standardization and optimization of AIC formulations for use in allergic patients.

KW - Anaphylaxis

KW - CpG motif immunotherapy

KW - Immunostimulatory DNA

UR - http://www.scopus.com/inward/record.url?scp=0036738405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036738405&partnerID=8YFLogxK

U2 - 10.1067/mai.2002.126660

DO - 10.1067/mai.2002.126660

M3 - Article

C2 - 12209088

AN - SCOPUS:0036738405

VL - 110

SP - 413

EP - 420

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -